While no statistically significant association was observed between starting dose and objective response rate (ORR) or clinical benefit rate (CBR), a numerical trend suggested that patients with shorter duration of response tended to have received lower initial doses [ 27 ].
← all excerpts
Sacituzumab Govitecan initial dose reduction in polish patients with metastatic triple-negative breast cancer: impact on efficacy and safety.
1
—
—